Cardiovascular safety concerns over smoking-cessation drug misleading

May 4, 2012, University of California, San Francisco

A popular smoking cessation medication has been under a cloud of suspicion ever since the Canadian Medical Association Journal (CMAJ) published a study in July 2011 reporting "risk of serious adverse cardiovascular events associated with varenicline." Varenicline, also known as Chantix, blocks the pleasant effects of nicotine on the smoker's brain and lessens nicotine withdrawal symptoms.

UCSF researchers, however, question the way the previous study was conducted, and their new analysis, scheduled to be published May 4 in BMJ, reaches a very different conclusion.

"We found no clinically or statistically significant increase in serious adverse cardiovascular events associated with using ," said lead author Judith J. Prochaska, PhD, MPH, an associate professor in UCSF's Department of Psychiatry and researcher with the Center for Tobacco Control Research and Education. "The findings from 22 trials with more than 9,200 participants indicate a difference in risk of only 0.27 percent between those on varenicline versus placebo, or about a quarter of one percent."

Prochaska identified the need for the re-analysis after reading the CMAJ publication and finding the conclusion inconsistent with the small differences within trials. Prochaska had received an "investigator-initiated research award" from Pfizer, the maker of Chantix, that spring for a separate study of varenicline in hospitalized smokers, many with . Prochaska says she was compelled to more closely examine the data to quantify the level of risk before using the medication on UCSF patients.

Differences in meta-analytic methods

Prochaska and Joan F. Hilton, ScD, MPH, a professor in UCSF's Department of Epidemiology & Biostatistics, conducted the new study, which, like the prior one, used meta-analytic statistical techniques to combine results from different trials of varenicline with tobacco users. The UCSF and prior analysis, however, differed in several fundamental ways.

The previous study, led by Sonal Singh, MD, MPH, assistant professor of medicine at Johns Hopkins University, looked at a sample size of 8,216 patients in 14 trials and reported a 72 percent (relative) increase in risk of heart attack or other serious heart problems.

The UCSF analysis included 22 double-blind, randomized controlled trials with 9,232 participants. More than half of the studies included participants with active or past history of cardiovascular disease. Eight trials had no events. The UCSF study found a 0.27 percent (absolute) risk difference, which it determined was neither clinically nor statistically significant.

"We identified eight separate trials with nearly 1,600 tobacco users randomized to varenicline or placebo that did not have a single serious cardiovascular event," Prochaska said. "This information is meaningful and the Singh analysis excluded these trials."

UCSF researchers say varenicline lasts in the body about seven days after a person stops using the medication. The new analysis examined events occurring during the drug treatment window or within 30 days after a patient stopped using the drug, rather than the entire trial period, which in many cases was a year in Singh's study.

"The longer you follow heavy, long-term tobacco users – and in these studies, the average participant smoked a pack a day for 25 years – the more likely you will see serious related to their compromised health," Prochaska said. "In addition, 13 of the 14 studies in the Singh analysis experienced greater attrition in the placebo group than in the test group, which could inflate the treatment effect."

Absolute difference vs. relative difference

Singh's study found that 1.06 percent of those who took varenicline had serious heart-related complications, compared to 0.82 percent of the placebo group. Although the simple absolute difference was only 0.24 percent – similar to the UCSF study finding based on meta-analysic methods– Singh's paper reported the weighted, relative difference, which was 72 percent.

"What made the headlines is this claim of a huge increase, but it's a relative measure; it's a unit-less measure," Prochaska said. "And so if you increase something small by a little bit, you can claim that it's a 72 percent increase, but that obscures the fact that it's still a very small risk."

"For someone not accustomed to these measures, it might not be obvious that the 72 percent increase was relative to a very small base – interpretations the Singh study didn't stress," Hilton said.

The new meta-analysis provides a more comprehensive examination of varenicline by presenting and comparing the four most relevant summary measures for this type of analysis.

"Among these, we found that the methods used by Singh and colleagues produced the most extreme estimates of treatment effect," said Hilton. "We identified the specific conditions under which this statistic is inflated. We recommended the summary based on the (absolute) risk difference because it is methodologically appropriate in our setting and gives a clear quantitative sense of the excess risk."

Smoking and cardiovascular risk

Cardiovascular disease is the leading cause of death among smokers. Tobacco use also increases a person's risk of stroke, cancer and lung disease.

"One of the most important things you can do for your heart is to quit smoking," Prochaska said. "Clinical practice guidelines recommend the use of FDA medications to quit smoking. All medications carry some risk; however, we hope the FDA and other experts compare the Singh analysis to ours to determine what action, if any, should be taken with regard to varenicline and cardiovascular risk. Tobacco is a deadly addiction, and patients need effective treatments."

Explore further: Varenicline for smoking cessation linked to increased risk of serious harmful cardiac events

Related Stories

Varenicline for smoking cessation linked to increased risk of serious harmful cardiac events

July 4, 2011
The use of varenicline to stop smoking is associated with a 72% increased risk of a serious adverse cardiovascular event, states an article in CMAJ (Canadian Medical Association Journal).

Benefits of Varenicline (Chantix) may balance certain risks

March 19, 2012
(Medical Xpress) -- The U.S. Food and Drug Administration (FDA) has approved the smoking cessation medication varenicline (Chantix) as an effective aide in helping people quit smoking, including those with cardiovascular ...

Chantix unsuitable for first-line smoking cessation use

November 2, 2011
The poor safety profile of the smoking-cessation drug varenicline (Chantix) makes it unsuitable for first-line use, according to a study published in the Nov. 2 edition of the journal PLoS One, an online publication of the ...

Starting smoking cessation medication earlier may make it easier to quit

January 5, 2012
Smokers planning to kick the habit may have more success if they begin using a cessation medication several weeks before they actually try to quit. Those are the results of a clinical trial conducted by researchers at the ...

Recommended for you

New study offers insights on genetic indicators of COPD risk

January 16, 2018
Researchers have discovered that genetic variations in the anatomy of the lungs could serve as indicators to help identify people who have low, but stable, lung function early in life, and those who are particularly at risk ...

Previous influenza virus exposures enhance susceptibility in another influenza pandemic

January 16, 2018
While past exposure to influenza A viruses often builds immunity to similar, and sometimes different, strains of the virus, Canadian researchers are calling for more attention to exceptions to that rule.

Don't hold your nose and close your mouth when you sneeze, doctors warn

January 15, 2018
Pinching your nose while clamping your mouth shut to contain a forceful sneeze isn't a good idea, warn doctors in the journal BMJ Case Reports.

New antifungal provides hope in fight against superbugs

January 12, 2018
Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant ...

Dengue takes low and slow approach to replication

January 11, 2018
A new study reveals how dengue virus manages to reproduce itself in an infected person without triggering the body's normal defenses. Duke researchers report that dengue pulls off this hoax by co-opting a specialized structure ...

Different strains of same bacteria trigger widely varying immune responses

January 11, 2018
Genetic differences between different strains of the same pathogenic bacterial species appear to result in widely varying immune system responses, according to new research published in PLOS Pathogens.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.